A Phase 2 interventional study of Tadalafil and Placebo in Benign Prostatic Hyperplasia, sponsored by Eli Lilly and Company. Completed at 5 sites in Korea, Republic of. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2010-11-25.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.
Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one is the 17th largest by enrollment, is the only one that started in 2007, is one of 4 in phase 2, and was the 3rd registered.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
Browse Prostatic Hyperplasia studies →2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:
Beni-Suef University · Sites in Egypt
Ages 50+ · Men only
Assiut University
Men only
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 45 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 11 · Phase 4 6
First in 2004; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 151 is above the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 258 across the 26 interventional studies. Of the 23 that completed or were terminated, 15 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 26 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
17 studies in Prostatic Hyperplasia by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 17 finished, 16 (94%) have results posted.
Among the 17 studies in Prostatic Hyperplasia by Eli Lilly and Company, this one is the 15th largest by enrollment, is the only one that started in 2007, is one of 5 in phase 2, and was the 3rd registered.
Eli Lilly and Company’s Prostatic Hyperplasia studies by the year they started, since 2004.
1 of the studies testing tadalafil in Prostatic Hyperplasia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07654413Beni-Suef UniversityTamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies testing tadalafil in Prostatic Hyperplasia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 17 in Prostatic Hyperplasia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this clinical trial is to evaluate the change in the International Prostate Symptom Score (IPSS) total score from the beginning of the study to the end of the study for subjects randomized to tadalafil 5mg once a day dosing and placebo once a day dosing for 12 weeks of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tadalafil
Drug: Placebo
Drug: Tamsulosin
5 mg once a day
Also known as: LY450190, Cialis
once a day
0.2 mg once a day
Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Total Score
The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.
Time frame: baseline, 12 weeks
Change From Baseline to 4 Week and 8 Week Endpoints in International Prostate Symptom Score (IPSS) Total Score
The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.
Time frame: baseline, 4 and 8 weeks
Change From Baseline to 4, 8, and 12 Week Endpoints in International Prostate Symptom Score (IPSS) - Irritative Subscore
The IPSS storage (irritative) subscore is defined as sum of scores for Questions 2, 4, and 7 of the IPSS. If scores for any of these questions are missing for a visit, the IPSS storage subscore will be reported as missing for that visit. Subscore totals range from 0 to 15; higher scores are indicative of greater irritation.
Time frame: baseline, 4, 8, and 12 weeks
Change From Baseline to 4, 8, and 12 Week Endpoints in International Prostate Symptom Score (IPSS) - Obstructive Subscore
The IPSS voiding (obstructive) subscore is defined as sum of scores for Questions 1, 3, 5, and 6 of the IPSS. If scores for any of these questions are missing for a visit, the IPSS voiding subscore will be reported as missing for that visit. Subscore totals range from 0 to 20; higher scores are indicative of greater obstruction.
Time frame: baseline, 4, 8, and 12 weeks
Change From Baseline to 4, 8, and 12 Week Endpoints in International Prostate Symptom Score (IPSS) - Nocturia Subscore
IPSS Question 7 is used to assess the frequency of nocturia. Scores range from 0 (low frequency of nocturia) to 5 (high frequency of nocturia).
Time frame: baseline, 4, 8, and 12 weeks
Change From Baseline to 12 Week Endpoint in Benign Prostatic Hyperplasia Impact Index (BPH-II)
The BPH-BII is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range of 0 to 13; higher scores represent increased perceived impact of BPH-LUTS on overall health. If scores for any component question were missing for a visit, BPH-BII was reported as missing for that visit.
Time frame: baseline, 12 weeks
Patient Global Impression of Improvement (PGI-I) Combined Categories - Frequencies
A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse). Scores were combined to provide number of participants who indicated they were "worse" (scores of 5, 6, or 7), "no change" (score of 4), or "better" (scores of 1, 2, or 3).
Time frame: 12 weeks
Clinician Global Impression of Improvement (CGI-I) Combined Categories - Frequencies
Measures clinician's perception of patient improvement of illness at the time of assessment compared with start of treatment. Scores range from 1 (very much better) to 7 (very much worse). Scores were combined to provide number of participants whose clinician indicated they were "worse" (scores of 5, 6, or 7), "no change" (score of 4), or "better" (scores of 1, 2, or 3).
Time frame: 12 weeks
Change From Baseline to 12 Week Endpoint in Total, Waking, and Sleeping Voids (Average Number Per Week) Based on Median as Reported in Patient Voiding Dribble Diary
Patient-completed diary that measures daytime frequency (waking voids) and nocturia (sleeping voids). Average number of waking voids per week, average number of sleeping voids per week, and average number of total voids (sleeping+waking) per week are reported.
Time frame: baseline, 12 weeks
Change From Baseline to 12 Week Endpoint in Total Urinary Incontinence Episodes Per Week Based on Median as Reported in Patient Voiding Dribble Diary
A patient-completed diary that measures urinary incontinence (UI) (leaks). Number of UI leaks per week are reported.
Time frame: baseline, 12 weeks
Change From Baseline to 12 Week Endpoint in Voids With Terminal Micturition Dribble and Post Micturition Dribble Per Week Based on Median as Reported by Patient Voiding Dribble Diary
A patient-completed diary that measures terminal dribble (dribble in the end of urination) and post-micturition dribble (dribble after urination).
Time frame: baseline, 12 weeks
Change From Baseline to 12 Week Endpoint in Uroflowmetry Parameters - Peak Urine Flow Rate (Qmax) and Mean Urine Flow Rate (Qmean)
Qmax: defined as the peak urine flow rate (measured in milliliters per second \[mL/second\] using a standard calibrated flowmeter); and Qmean, defined as the mean urine flow rate (measured in mL/second using a standard calibrated flowmeter).
Time frame: baseline, 12 weeks
Change From Baseline to 12 Week Endpoint in Uroflowmetry Parameters - Voided Urine Volume (Vcomp)
Vcomp, defined as the volume of voided urine (measured in milliliters \[mL\]).
Time frame: baseline, 12 weeks
| Milestone | Placebo | Tadalafil | Tamsulosin |
|---|---|---|---|
| Started | 51 | 51 | 49 |
| Completed | 47 | 48 | 48 |
| Not completed | 4 | 3 | 1 |
| Withdrew: Adverse event | 0 | 2 | 1 |
| Withdrew: Entry criteria not met | 2 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 |
The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.
| units on a scale | Placebo | Tadalafil | Tamsulosin |
|---|---|---|---|
| Baseline | 17.3 ± 5.0 | 17.1 ± 5.4 | 17.7 ± 5.0 |
| 12 Week Change | -4.2 ± 4.8 | -5.8 ± 4.6 | -5.6 ± 5.3 |
The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.
| units on a scale | Placebo | Tadalafil | Tamsulosin |
|---|---|---|---|
| 4 Week Change (n=50, n=49, n=49) | -2.8 ± 0.6 | -4.0 ± 0.6 | -4.0 ± 0.6 |
| 8 Week Change (n=47, n=50, n=48) | -3.3 ± 0.7 | -4.8 ± 0.6 | -4.8 ± 0.7 |
The IPSS storage (irritative) subscore is defined as sum of scores for Questions 2, 4, and 7 of the IPSS. If scores for any of these questions are missing for a visit, the IPSS storage subscore will be reported as missing for that visit. Subscore totals range from 0 to 15; higher scores are indicative of greater irritation.
| units on a scale | Placebo | Tadalafil | Tamsulosin |
|---|---|---|---|
| Baseline (n=50, n=50, n=49) | 6.7 ± 2.0 | 6.7 ± 2.7 | 6.5 ± 2.6 |
| 4 Week Change (n=50, n=49, n=49) | -0.8 ± 2.1 | -1.4 ± 2.4 | -1.7 ± 2.1 |
| 8 Week Change (n=47, n=50, n=48) | -0.9 ± 2.0 | -1.6 ± 2.5 | -1.9 ± 2.3 |
| 12 Week Change (n=47, n=48, n=48) | -1.6 ± 2.1 | -2.2 ± 2.4 | -1.8 ± 2.7 |
The IPSS voiding (obstructive) subscore is defined as sum of scores for Questions 1, 3, 5, and 6 of the IPSS. If scores for any of these questions are missing for a visit, the IPSS voiding subscore will be reported as missing for that visit. Subscore totals range from 0 to 20; higher scores are indicative of greater obstruction.
| units on a scale | Placebo | Tadalafil | Tamsulosin |
|---|---|---|---|
| Baseline (n=50, n=50, n=49) | 10.6 ± 3.7 | 10.4 ± 3.8 | 11.2 ± 3.7 |
| 4 Week Change (n=50, n=49, n=49) | -2.0 ± 4.0 | -2.6 ± 3.1 | -2.4 ± 3.1 |
| 8 Week Change (n=47, n=50, n=48) | -2.3 ± 4.1 | -3.1 ± 3.1 | -3.1 ± 3.8 |
| 12 Week Change (n=47, n=48, n=48) | -2.7 ± 3.6 | -3.6 ± 3.4 | -3.9 ± 3.6 |
IPSS Question 7 is used to assess the frequency of nocturia. Scores range from 0 (low frequency of nocturia) to 5 (high frequency of nocturia).
| units on a scale | Placebo | Tadalafil | Tamsulosin |
|---|---|---|---|
| Baseline (n=50, n=50, n=49) | 2.0 ± 1.1 | 1.8 ± 1.0 | 1.7 ± 1.0 |
| 4 Week Change (n=50, n=49, n=49) | -0.3 ± 0.9 | -0.4 ± 0.9 | -0.3 ± 1.0 |
| 8 Week Change (n=47, n=50, n=48) | -0.4 ± 0.7 | -0.4 ± 1.0 | -0.4 ± 1.2 |
| 12 Week Change (n=47, n=48, n=48) | -0.5 ± 0.9 | -0.5 ± 0.9 | -0.5 ± 1.1 |
The BPH-BII is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range of 0 to 13; higher scores represent increased perceived impact of BPH-LUTS on overall health. If scores for any component question were missing for a visit, BPH-BII was reported as missing for that visit.
| units on a scale | Placebo | Tadalafil | Tamsulosin |
|---|---|---|---|
| Baseline | 6.2 ± 2.8 | 6.1 ± 2.9 | 6.2 ± 3.1 |
| 12 Week Change | -2.0 ± 2.7 | -2.2 ± 2.9 | -1.7 ± 2.6 |
A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse). Scores were combined to provide number of participants who indicated they were "worse" (scores of 5, 6, or 7), "no change" (score of 4), or "better" (scores of 1, 2, or 3).
| participants | Placebo | Tadalafil | Tamsulosin |
|---|---|---|---|
| Worse | 1 | 1 | 3 |
| No Change | 10 | 5 | 7 |
| Better | 37 | 43 | 38 |
Measures clinician's perception of patient improvement of illness at the time of assessment compared with start of treatment. Scores range from 1 (very much better) to 7 (very much worse). Scores were combined to provide number of participants whose clinician indicated they were "worse" (scores of 5, 6, or 7), "no change" (score of 4), or "better" (scores of 1, 2, or 3).
| participants | Placebo | Tadalafil | Tamsulosin |
|---|---|---|---|
| Worse | 0 | 0 | 4 |
| No Change | 5 | 8 | 4 |
| Better | 43 | 41 | 40 |
Patient-completed diary that measures daytime frequency (waking voids) and nocturia (sleeping voids). Average number of waking voids per week, average number of sleeping voids per week, and average number of total voids (sleeping+waking) per week are reported.
| average number per week | Placebo | Tadalafil | Tamsulosin |
|---|---|---|---|
| Baseline Waking Voids | 48.2 ± 11.2 | 46.9 ± 11.1 | 48.4 ± 16.9 |
| 12 Week Change Waking Voids | -0.3 ± 8.7 | -2.1 ± 8.7 | -1.3 ± 7.6 |
| Baseline Sleeping Voids | 10.3 ± 7.8 | 9.8 ± 6.7 | 7.9 ± 5.4 |
| 12 Week Change Sleeping Voids | -1.3 ± 3.5 | -2.3 ± 3.8 | -1.4 ± 4.0 |
| Baseline Total Voids | 58.6 ± 13.0 | 56.7 ± 13.3 | 56.3 ± 19.2 |
| 12 Week Change Total Voids | -1.6 ± 9.2 | -4.4 ± 9.7 | -2.7 ± 8.9 |
A patient-completed diary that measures urinary incontinence (UI) (leaks). Number of UI leaks per week are reported.
| average number per week | Placebo | Tadalafil | Tamsulosin |
|---|---|---|---|
| Baseline | 0.8 ± 3.6 | 1.1 ± 5.4 | 1.6 ± 5.0 |
| 12 Week Change | -0.3 ± 3.5 | 0.7 ± 2.5 | -0.3 ± 4.9 |
A patient-completed diary that measures terminal dribble (dribble in the end of urination) and post-micturition dribble (dribble after urination).
| average number per week | Placebo | Tadalafil | Tamsulosin |
|---|---|---|---|
| Baseline Terminal Micturation Dribble | 68.7 ± 35.8 | 69.8 ± 37.0 | 77.5 ± 29.9 |
| 12 Week Change Terminal Micturation Dribble | -11.7 ± 36.9 | 1.6 ± 31.9 | -8.5 ± 33.1 |
| Baseline Post Micturation Dribble | 14.3 ± 27.0 | 17.8 ± 29.8 | 25.5 ± 32.6 |
| 12 Week Change Post Micturation Dribble | -0.8 ± 29.5 | -4.8 ± 27.4 | -7.6 ± 34.9 |
Qmax: defined as the peak urine flow rate (measured in milliliters per second \[mL/second\] using a standard calibrated flowmeter); and Qmean, defined as the mean urine flow rate (measured in mL/second using a standard calibrated flowmeter).
| milliliters per second | Placebo | Tadalafil | Tamsulosin |
|---|---|---|---|
| Baseline Qmax | 10.5 ± 3.6 | 11.4 ± 3.2 | 11.7 ± 4.6 |
| 12 Week Change Qmax | 2.8 ± 5.6 | 2.4 ± 5.2 | 1.9 ± 4.8 |
| Baseline Qmean | 5.7 ± 2.3 | 6.1 ± 2.1 | 6.2 ± 3.0 |
| 12 Week Change Qmean | 2.0 ± 3.1 | 1.5 ± 2.9 | 1.0 ± 3.4 |
Vcomp, defined as the volume of voided urine (measured in milliliters \[mL\]).
| milliliters | Placebo | Tadalafil | Tamsulosin |
|---|---|---|---|
| Baseline | 220.0 ± 67.7 | 233.2 ± 86.7 | 236.6 ± 78.4 |
| 12 Week Change | 21.4 ± 128.9 | 19.7 ± 109.2 | 23.9 ± 89.3 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | — | — |
| Tadalafil | — | — | — |
| Tamsulosin | — | — | — |
| Event | Placebo | Tadalafil | Tamsulosin |
|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/51 | 0/51 | 1/49 |
| Inguinal herniaGastrointestinal disorders | 0/51 | 0/51 | 1/49 |
| Lumbar spinal stenosisMusculoskeletal and connective tissue disorders | 0/51 | 1/51 | 0/49 |
| Lung adenocarcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/51 | 1/51 | 0/49 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/51 | 1/51 | 0/49 |
| Event | Placebo | Tadalafil | Tamsulosin |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 0/51 | 1/51 | 5/49 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/51 | 2/51 | 1/49 |
| DyspepsiaGastrointestinal disorders | 0/51 | 0/51 | 1/49 |
| Epigastric discomfortGastrointestinal disorders | 0/51 | 0/51 | 1/49 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 0/51 | 0/51 | 1/49 |
| Chest painGeneral disorders | 0/51 | 0/51 | 1/49 |
| Intentional overdoseInjury, poisoning and procedural complications | 0/51 | 1/51 | 1/49 |
| Skin lacerationInjury, poisoning and procedural complications | 0/51 | 0/51 | 1/49 |
| HyperlipidaemiaMetabolism and nutrition disorders | 0/51 | 0/51 | 1/49 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/51 | 0/51 | 1/49 |
| Age Continuous(years) | Placebo | Tadalafil | Tamsulosin | Total |
|---|---|---|---|---|
| Mean | 62.2 ± 6.8 | 61.2 ± 6.6 | 61.5 ± 6.4 | 61.6 ± 6.6 |
| Sex: Female, Male(Participants) | Placebo | Tadalafil | Tamsulosin | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 51 | 51 | 49 | 151 |
| Race (NIH/OMB)(Participants) | Placebo | Tadalafil | Tamsulosin | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 51 | 51 | 49 | 151 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Placebo | Tadalafil | Tamsulosin | Total |
|---|---|---|---|---|
| Korea, Republic of | 51 | 51 | 49 | 151 |
| Erectile Dysfunction (ED)(participants) | Placebo | Tadalafil | Tamsulosin | Total |
|---|---|---|---|---|
| Yes | 36 | 30 | 24 | 90 |
| No | 15 | 21 | 25 | 61 |
| Duration of Erectile Dysfunction (ED)(participants) | Placebo | Tadalafil | Tamsulosin | Total |
|---|---|---|---|---|
| <3 Months | 0 | 1 | 0 | 1 |
| 3 Months to < 6 Months | 2 | 3 | 1 | 6 |
| 6 Months to < 1 Year | 5 | 3 | 5 | 13 |
| 1 Year or More | 29 | 23 | 18 | 70 |
| Etiology of Erectile Dysfunction (ED)(participants) | Placebo | Tadalafil | Tamsulosin | Total |
|---|---|---|---|---|
| Psychogenic | 2 | 0 | 0 | 2 |
| Organic | 16 | 10 | 11 | 37 |
| Mixed | 17 | 15 | 12 | 44 |
| Unknown | 1 | 5 | 1 | 7 |
| Severity of Erectile Dysfunction (ED)(participants) | Placebo | Tadalafil | Tamsulosin | Total |
|---|---|---|---|---|
| Mild | 17 | 22 | 13 | 52 |
| Moderate | 14 | 5 | 7 | 26 |
| Severe | 5 | 3 | 4 | 12 |
5 further baseline measures are reported on the registry.
The record gives a start of Oct 2007, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil